{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:19:34Z","timestamp":1761898774673,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clinre.2022.101920","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T20:55:57Z","timestamp":1649105757000},"page":"101920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin"],"prefix":"10.1016","volume":"46","author":[{"given":"Diana Maria","family":"Bran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fuks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Lansier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Gallois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Karoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Widad","family":"Lahlou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2022.101920_bib0001","unstructured":"Malka D, et al. Cancer des voies biliaires. Th\u00e9saurus National de Canc\u00e9rologie Digestive, 2019, en ligne [http:\/\/www.tncd.org]."},{"issue":"2","key":"10.1016\/j.clinre.2022.101920_bib0002","first-page":"306\u201110","article-title":"Trends in the incidence and management of biliary tract cancer: a French population-based study","volume":"54","author":"Lepage","year":"2011","journal-title":"J Hepatol. f\u00e9vr"},{"issue":"suppl 5","key":"10.1016\/j.clinre.2022.101920_bib0003","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol Off J Eur Soc Med Oncol. sept"},{"issue":"5","key":"10.1016\/j.clinre.2022.101920_bib0004","first-page":"663\u201173","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol. mai"},{"issue":"5","key":"10.1016\/j.clinre.2022.101920_bib0005","first-page":"690\u2011701","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol. mai"},{"issue":"4_suppl","key":"10.1016\/j.clinre.2022.101920_bib0006","first-page":"378\u2011378","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1","volume":"40","author":"Oh","year":"2022","journal-title":"J Clin Oncol. 1 f\u00e9vr"},{"issue":"1","key":"10.1016\/j.clinre.2022.101920_bib0007","first-page":"170\u201185","article-title":"Molecular targeted therapies: Ready for \u00ab prime time \u00bb in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol. juill"},{"issue":"9","key":"10.1016\/j.clinre.2022.101920_bib0008","first-page":"557\u201188","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol. sept"},{"issue":"1","key":"10.1016\/j.clinre.2022.101920_bib0009","first-page":"120\u20117","article-title":"Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis","volume":"41","author":"Al-Adra","year":"2015","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. janv"},{"issue":"3","key":"10.1016\/j.clinre.2022.101920_bib0010","first-page":"353\u201161","article-title":"Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution","volume":"16","author":"Burger","year":"2005","journal-title":"J Vasc Interv Radiol JVIR. mars"},{"issue":"12","key":"10.1016\/j.clinre.2022.101920_bib0011","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.3390\/cancers13123091","article-title":"Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art","volume":"13","author":"Laface","year":"2021","journal-title":"Cancers. 21 juin"},{"issue":"5","key":"10.1016\/j.clinre.2022.101920_bib0012","doi-asserted-by":"crossref","first-page":"354\u201160","DOI":"10.1159\/000362223","article-title":"Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience","volume":"59","author":"Ghiringhelli","year":"2013","journal-title":"Chemotherapy"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122000638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122000638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:33:06Z","timestamp":1761895986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740122000638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2210740122000638"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2022.101920","relation":{},"ISSN":["2210-7401"],"issn-type":[{"type":"print","value":"2210-7401"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2022.101920","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101920"}}